HIV-1-INFECTION

This early-stage study is testing the safety and immune response of two different HIV vaccine regimens in healthy adults without HIV. The research aims to see if a new two-part vaccination approach can train the body's immune system to produce antibodies that could potentially bl…

This is the first human trial testing two new HIV vaccine candidates called DV700P-RNA and DV701B1.1-RNA. The study aims to check if these vaccines are safe and how well they trigger immune responses in healthy adults without HIV. Forty-five volunteers aged 18-55 will participate…

This is the first human study of two experimental HIV vaccines given in combination. Researchers want to see if the vaccines are safe and if they trigger a strong immune response in healthy volunteers without HIV. The study will enroll 25 participants who will be monitored for ab…

This study is testing if people with well-controlled HIV can safely switch from taking daily pills to a new, experimental weekly oral tablet. The goal is to see if the weekly medication works as well as the current standard daily treatment at keeping the virus suppressed. The stu…

This study is checking for any long-term safety problems in people who previously received an experimental gene therapy for HIV. The therapy involved modifying a person's own blood cells to help them fight the virus. Researchers are following 11 participants to see if any delayed…

This study is testing if switching to a new two-drug combination pill (bictegravir/lenacapavir) works as well as staying on the current standard three-drug pill (Biktarvy) for people whose HIV is already under control. It involves about 577 adults who have had their virus suppres…

This study is testing if switching older adults with well-controlled HIV from a three-drug pill to a simpler two-drug pill is just as effective and safe. It involves 240 participants in Kenya aged 60 and over who will take the new pill for two years. The main goal is to see if th…

This study is testing whether switching to a new two-drug combination (bictegravir plus lenacapavir) works as well as a person's current complex HIV medication regimen. It involves nearly 700 people whose HIV is already well-controlled. The main goal is to see if the new combinat…

This study is testing whether simple urine tests that check if people are taking their HIV medication properly and measure their virus levels can help people stay on treatment longer and keep the virus under control. The research involves 539 people in South Africa who are starti…

This study is testing whether a 6-month home-based walking program can improve metabolic health markers like blood sugar and cholesterol in people with and without HIV. Participants will gradually increase their daily steps to about 10,000, tracked with an activity monitor. The g…

This study is testing whether a new combination of two experimental drugs, taken just once a week by mouth, is as safe and effective as the current standard daily pill (Biktarvy) for treating HIV. It will involve 675 adults who are starting HIV treatment for the first time. The m…

This study is testing a single, once-daily pill containing three HIV medicines in children and adolescents. The main goals are to understand how the drug works in younger bodies, confirm the right dose, and check its safety and effectiveness at keeping the virus under control. It…

This study is testing a new weekly pill combination (islatravir + lenacapavir) for people with HIV whose virus is already well-controlled on daily medication. The main goal is to see if the weekly pills are as effective at keeping the virus suppressed after 24 weeks. It involves …

This study is testing a new once-daily pill combination (doravirine/islatravir) for people who have HIV but have never taken medication for it. It will compare this new pill to a standard HIV treatment to see if it works just as well at keeping the virus under control and if it i…

This study is testing if people with HIV who are already successfully controlling their virus can safely switch to a new, simpler two-drug pill (doravirine/islatravir) taken once daily. It compares this new pill to people continuing their current HIV medications to see if it work…

This study is testing a new long-acting HIV drug called lenacapavir for people whose current medications are failing due to drug resistance. It involves about 72 adults and adolescents whose HIV is resistant to most available drug classes. The goal is to see if adding this new dr…

This study is testing if people with HIV who have their virus well-controlled on a standard three-drug pill can safely switch to a new two-drug pill (Doravirine/Islatravir). It will compare the new pill to staying on the current treatment to see if it works just as well at keepin…

This study allows people with HIV-1 who benefited from the two-drug combination doravirine/islatravir in earlier trials to continue receiving it. The main goal is to monitor the long-term safety and side effects of this treatment. It is open to about 2000 participants who are alr…

This study is testing whether a new combination of two experimental drugs, taken just once a week, is as safe and effective as the current standard daily pill for managing HIV. It involves about 675 adults whose HIV is already well-controlled with daily medication. The goal is to…

This study is testing if people with well-controlled HIV can safely switch from taking daily medication to a new weekly pill. It will compare the weekly pill (islatravir/lenacapavir) to continuing their current standard treatment. The main goal is to see if the weekly pill keeps …

This study is testing whether the 9-valent HPV vaccine can prevent persistent oral HPV infections in men living with HIV. It involves 700 adult men who will receive either the real vaccine or a placebo over several months. Researchers will track whether the vaccine reduces new, l…

This study is testing two different ways to train HIV clinic staff in Vietnam to deliver a brief alcohol counseling program to their patients. The goal is to see which training method helps clinics do a better job of offering this counseling, which aims to reduce unhealthy drinki…

This study aims to better understand how HIV hides in the body even when patients are on effective treatment. Researchers will measure specific markers on immune cells and viral DNA in 48 adults who have had undetectable HIV levels for at least two years. The goal is to learn mor…